Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on May 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

BridgeBio Pharma Price Performance

NASDAQ:BBIO opened at $67.40 on Thursday. BridgeBio Pharma, Inc. has a one year low of $38.57 and a one year high of $84.94. The company has a market cap of $13.20 billion, a P/E ratio of -18.02 and a beta of 0.97. The firm’s fifty day moving average price is $70.51 and its two-hundred day moving average price is $72.15.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.52 million for the quarter, compared to the consensus estimate of $178.07 million. The business’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.88) earnings per share. As a group, equities research analysts expect that BridgeBio Pharma, Inc. will post -2.32 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new position in BridgeBio Pharma during the third quarter worth about $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma during the third quarter worth about $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the first quarter worth about $35,000. Huntington National Bank raised its stake in BridgeBio Pharma by 111.7% during the third quarter. Huntington National Bank now owns 743 shares of the company’s stock worth $39,000 after acquiring an additional 392 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after acquiring an additional 245 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $67.90, for a total value of $2,716,000.00. Following the completion of the transaction, the chief executive officer owned 575,686 shares of the company’s stock, valued at $39,089,079.40. This represents a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,651 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $65.08, for a total value of $888,407.08. Following the completion of the transaction, the chief financial officer directly owned 359,194 shares of the company’s stock, valued at $23,376,345.52. This represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 171,754 shares of company stock worth $11,914,859 in the last ninety days. Insiders own 14.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BBIO. Mizuho reissued an “outperform” rating and issued a $106.00 target price on shares of BridgeBio Pharma in a research report on Tuesday, April 28th. William Blair initiated coverage on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. They issued an “outperform” rating for the company. Oppenheimer cut their price objective on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. Citigroup initiated coverage on shares of BridgeBio Pharma in a research report on Tuesday, May 19th. They set a “neutral” rating and a $82.00 price objective for the company. Finally, Canaccord Genuity Group initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 price objective for the company. Twenty-three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average target price of $89.59.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.